 Home > Active Ingredient News > Blood System > NEJM: Darlimumab combination therapy can help improve the prognosis of newly diagnosed AL amyloid patients

NEJM: Darlimumab combination therapy can help improve the prognosis of newly diagnosed AL amyloid patients

 Last Update: 2021-08-02
 Source: Internet
 Author: User

Tags

dexamethasone injection site

response results

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Immune immunoglobulin light chain (AL) amyloidosis is a clonal, non-plasma cell proliferative diseases, immunoglobulins which may be deposited in different parts of the tissue or organ, and leads to a series of symptoms, such as restrictive cardiomyopathy The clonal expansion of CD38+ plasma cells is an important pathogenesis mechanism for diseases, nephrotic syndrome, liver failure, peripheral/autonomic neuropathy, and asymptomatic multiple myeloma
.

The current standard treatment regimen is the use of multiple myeloma-derived targeted plasma cell therapy--that is, a combination of bortezomib, cyclophosphamide and dexamethasone

Immune Recently researchers have investigated over new diagnostic clinical results of patients with AL amyloidosis

Newly diagnosed patients with AL amyloidosis participated in the study.
On the basis of 6 rounds of bortezomib-cyclophosphamide-dexamethasone combination therapy, they were randomized to receive placebo or darelimumab treatment, darelimumab group A subcutaneous injection is given every 4 weeks for a maximum of 24 rounds
.

The primary endpoint of the study was a complete hematological response

A total of 388 patients participated in the study, with an average follow-up time of 11.
4 months
.

The hematological complete response rate in the darlimumab group was significantly higher than that in the control group (53.

No major organ deterioration or no hematological progression difference in survival rate between groups

Studies believe that for newly diagnosed AL amyloid patients, the addition of CD38 darrimumab to the combination therapy of bortezomib, cyclophosphamide and dexamethasone can help improve the patient’s complete hematological response rate and reduce the deterioration or deterioration of major organs.

For newly diagnosed patients with AL amyloid, the addition of CD38 darimumab to the combined treatment of bortezomib, cyclophosphamide and dexamethasone can help improve the patient’s complete hematological response rate and reduce the risk of major organ deterioration or hematological progression For newly diagnosed patients with AL amyloid, the addition of CD38 darimumab to the combined treatment of bortezomib, cyclophosphamide and dexamethasone can help improve the patient’s complete hematological response rate and reduce the risk of major organ deterioration or hematological progression

Original source:

Efstathios Kastritis et al.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.